Batalov Zguro, Sapundzhieva Tanya, Batalov Konstantin, Karalilova Rositsa, Batalov Anastas
Medical Faculty, Medical University, 4000 Plovdiv, Bulgaria.
Rheumatology Clinic, University Hospital 'Kaspela', 4000 Plovdiv, Bulgaria.
Diagnostics (Basel). 2025 Jul 10;15(14):1753. doi: 10.3390/diagnostics15141753.
To assess the role of musculoskeletal ultrasound (MSUS) in selecting patients with rheumatoid arthritis (RA) in sustained clinical remission, suitable for tapering of biologic therapy (BT), and monitoring for a subclinical relapse. In this prospective study, seventy-eight patients with RA in sustained Disease Activity for twenty-eight joints (DAS28) clinical remission underwent ultrasound (US) examination of twenty-two joints (bilaterally wrists and metacarpophalangeal and proximal interphalangeal joints). US assessment was performed on gray scale ultrasound (GSUS) and power Doppler US (PDUS) to select patients in imaging remission, defined as a total PD score of synovitis = 0. Group 1 consisted of patients in clinical and imaging remission, in which tapering of BT was done through spacing of the Tumour Necrosis Factor Alpha (TNF-α) blocker. Group 2 consisted of patients only in clinical remission (PDUS > 0), who continued standard therapy. Clinical and US assessment was done at months 6 and 12, and the rate of a clinical (defined as DAS28 ≥ 2.6) and an US relapse (PDUS score ≥ 1) was recorded. Thirty-eight patients were in clinical and US remission (group 1) and forty patients only in clinical remission (group 2). At month 6, 26% of patients in group 1 and 10% in group 2 experienced a clinical and an US relapse, whereas 20% and 15% of them, respectively, only an US relapse. At month 12, 26% of patients in group 1 and 20% of patients in group 2 experienced a clinical and an US relapse, whereas 35% and 22% of them, respectively, only an US relapse. Real-world data show that MSUS is a useful tool to identify RA patients in sustained clinical remission appropriate for BT tapering. US monitoring could predict a clinical relapse and the need to re-escalate treatment in patients with subclinical US relapse during BT tapering.
评估肌肉骨骼超声(MSUS)在选择处于持续临床缓解期、适合逐渐减少生物治疗(BT)以及监测亚临床复发的类风湿关节炎(RA)患者中的作用。在这项前瞻性研究中,78例处于28关节疾病活动度(DAS28)持续临床缓解期的RA患者接受了22个关节(双侧手腕、掌指关节和近端指间关节)的超声(US)检查。通过灰阶超声(GSUS)和能量多普勒超声(PDUS)进行US评估,以选择处于影像缓解期的患者,影像缓解期定义为滑膜炎的总PD评分为0。第1组由处于临床和影像缓解期的患者组成,其中通过间隔使用肿瘤坏死因子α(TNF-α)阻滞剂来逐渐减少BT。第2组由仅处于临床缓解期(PDUS>0)的患者组成,他们继续接受标准治疗。在第6个月和第12个月进行临床和US评估,并记录临床复发率(定义为DAS28≥2.6)和US复发率(PDUS评分≥1)。38例患者处于临床和US缓解期(第1组),40例患者仅处于临床缓解期(第2组)。在第6个月时,第1组中26%的患者和第2组中10%的患者经历了临床和US复发,而分别有20%和15%的患者仅出现US复发。在第12个月时,第1组中26%的患者和第2组中20%的患者经历了临床和US复发,而分别有35%和22%的患者仅出现US复发。真实世界数据表明,MSUS是识别适合逐渐减少BT的持续临床缓解期RA患者的有用工具。US监测可以预测临床复发以及在BT逐渐减少过程中出现亚临床US复发的患者重新加大治疗力度的必要性。